Belzutifan for advanced kidney cancer: long-term follow-up
Studies looking at the genes of people with kidney cancer have shown [...]
ESMO 2023: New online educational programme for kidney cancer nurses
Action Kidney Cancer have been involved with the development of [...]
Artificial intelligence has potential to improve urology services
There has been growing interest around the use artificial intelligence [...]
New treatment, zanzalintinib, for advanced kidney cancer
A recent clinical trial looked at a new anti-cancer medication [...]
Real world treatment of advanced kidney cancer
Nearly 30% of new kidney cancer cases are diagnosed at [...]
ESMO 2023: Does stopping VEGFR TKI treatment and continuing immunotherapy influence the survival of patients on combination therapy?
In many countries, combinations of VEGFR TKI anti-cancer mediations plus [...]
ESMO 2023: A new immunotherapy, volrustomig, for the first-line treatment of advanced kidney cancer
Blocking the action of two proteins in cancer cells (PD-1 [...]
ESMO 2023: A new first-line treatment, toripalimab, for advanced kidney cancer
Advanced/metastatic kidney cancer is often treated with a combination of [...]
ESMO 2023: Belzutifan for the treatment of advanced kidney cancer
Treatments for people with metastatic kidney cancer have changed over [...]
Action Kidney Cancer at the ESMO Congress
Steve Pointon, person centred counsellor kidney cancer patient and one of [...]
